Buscar
Mostrando ítems 1-7 de 7
Artículo
Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort
(Elsevier Science BV, 2022)
Background: Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Methods: Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), ...
Artículo
Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naïve schizophrenia
(ACADEMIC PRESS INC ELSEVIER SCIENCE, 2022)
Despite being a major cause of disability worldwide, the pathophysiology of schizophrenia and molecular basis of treatment response heterogeneity continue to be unresolved. Recent evidence suggests that multiple aspects ...
Artículo
Pattern of long-term weight and metabolic changes after a first episode of psychosis Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort
(Cambridge University Press, 2022-08-16)
Background People with psychosis are at higher risk of cardiovascular events, partly explained by a higher predisposition to gain weight. This has been observed in studies on individuals with a first-episode psychosis ...
Artículo
Gene set enrichment analysis of pathophysiological pathways highlights oxidative stress in psychosis
(Springer Nature, 2022-09-21)
Polygenic risk prediction remains an important aim of genetic association studies. Currently, the predictive power of schizophrenia polygenic risk scores (PRSs) is not large enough to allow highly accurate discrimination ...
Artículo
Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
(Oxford University Press, 2022-07-27)
Background Antipsychotic choice for the acute phase of a first episode of psychosis (FEP) is of the utmost importance since it may influence long-term outcome. However, head-to-head comparisons between second-generation ...
Artículo
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis
(Oxford University Press, 2022-05-31)
Objective Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. ...
Artículo
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples
(Elsevier, 2022-08-19)
Background Cardiometabolic dysfunction is common in young people with psychosis. Recently, the Psychosis Metabolic Risk Calculator (PsyMetRiC) was developed and externally validated in the UK, predicting up-to six-year ...